Published

Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: PLoS ONE
Date: 2010-12-01
Source: OpenAlex
DOI: 10.1371/journal.pone.0014074
PubMed: 21152030

Authors

Matthew J. Baggott Jennifer D. Siegrist Gantt P. Galloway Lynn C. Robertson Jeremy Coyle John Mendelson

Watch author

Derived topics and classifications

psilocybin Pharmacology Mechanism of Action Receptor Pharmacology Mystical Experience Randomized Controlled Trial Toxicity Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans2010-12-01

Related papers

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyClinicalTrials.gov · 2023-03-20